Mozart Therapeutics website screenshot

Mozart Therapeutics

Mozart Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company in Seattle, Washington, founded in 2020 to develop disease-modifying therapies for autoimmune and inflammatory disease. Its platform is built on the regulatory CD8 T cell (CD8 Treg) network — an upstream immune checkpoint that normally recognizes and eliminates the pathogenic immune cells that attack healthy tissue, and that becomes dysfunctional in autoimmune disease when inhibitory killer immunoglobulin-like receptors (KIR) block CD8 Treg activation. Rather than suppressing downstream inflammation, Mozart engineers bispecific CD8 Treg modulators intended to restore that checkpoint and re-establish long-term immune balance. Its pipeline comprises MTX-101, a KIR x CD8 bispecific antibody in Phase 1b study for type 1 diabetes, and MTX-201, a KIR x ICOS bispecific in preclinical development for inflammatory bowel disease. The company launched with a $55M Series A led by ARCH Venture Partners and Sofinnova Partners with participation from Eli Lilly, MRL Ventures Fund, Leaps by Bayer, Altitude Life Science Ventures and Alexandria Venture Investments, and later added a $25M extension including Pfizer Ventures, AbbVie Ventures, Ono Venture Investment and UPMC Enterprises. Mozart Therapeutics sells therapeutics, not software: it runs no developer program, publishes no API, SDK or machine-readable specification, and maintains no public source-code organization.

Mozart Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Immunology, and Autoimmune Disease.

Mozart Therapeutics’ developer surface includes product news and 9 more developer resources.

3.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-09-02 · rubric v0.18.0
0 APIs
CompanyBiotechnologyPharmaceuticalsImmunologyAutoimmune DiseaseDrug DiscoveryLife SciencesClinical TrialsBispecific AntibodiesResearch

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-09-02 · rubric v0.18.0
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/mozart-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Resources

Access & Security 1

Authentication, authorization, and security posture

Operate 1

Status, limits, changes, and where to get help

Company 5

The organization behind the API

Other 3

Properties that don't map to a standard resource type

Source (apis.yml)

apis.yml Raw ↑
aid: mozart-therapeutics
name: Mozart Therapeutics
description: 'Mozart Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company in Seattle, Washington,
  founded in 2020 to develop disease-modifying therapies for autoimmune and inflammatory disease. Its platform is built on
  the regulatory CD8 T cell (CD8 Treg) network — an upstream immune checkpoint that normally recognizes and eliminates the
  pathogenic immune cells that attack healthy tissue, and that becomes dysfunctional in autoimmune disease when inhibitory
  killer immunoglobulin-like receptors (KIR) block CD8 Treg activation. Rather than suppressing downstream inflammation, Mozart
  engineers bispecific CD8 Treg modulators intended to restore that checkpoint and re-establish long-term immune balance.
  Its pipeline comprises MTX-101, a KIR x CD8 bispecific antibody in Phase 1b study for type 1 diabetes, and MTX-201, a KIR
  x ICOS bispecific in preclinical development for inflammatory bowel disease. The company launched with a $55M Series A led
  by ARCH Venture Partners and Sofinnova Partners with participation from Eli Lilly, MRL Ventures Fund, Leaps by Bayer, Altitude
  Life Science Ventures and Alexandria Venture Investments, and later added a $25M extension including Pfizer Ventures, AbbVie
  Ventures, Ono Venture Investment and UPMC Enterprises. Mozart Therapeutics sells therapeutics, not software: it runs no
  developer program, publishes no API, SDK or machine-readable specification, and maintains no public source-code organization.'
url: https://raw.githubusercontent.com/api-evangelist/mozart-therapeutics/refs/heads/main/apis.yml
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://www.mozart-tx.com/themes/default/images/logo_color.svg
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pipeline
specificationVersion: '0.23'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Immunology
- Autoimmune Disease
- Drug Discovery
- Life Sciences
- Clinical Trials
- Bispecific Antibodies
- Research
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/mozart-therapeutics-domain-security.yml
- type: Website
  url: https://www.mozart-tx.com/
- type: About
  url: https://www.mozart-tx.com/about/
- type: Science
  url: https://www.mozart-tx.com/science/
- type: Pipeline
  url: https://www.mozart-tx.com/pipeline/
- type: News
  url: https://www.mozart-tx.com/news/news-releases/
- type: Careers
  url: https://www.mozart-tx.com/careers/
- type: Contact
  url: https://www.mozart-tx.com/contact/
- type: LinkedIn
  url: https://www.linkedin.com/company/mozart-therapeutics
- type: SecondaryMarket
  url: https://forgeglobal.com/mozart-therapeutics_stock/
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Mozart Therapeutics is a privately held clinical-stage biopharmaceutical company whose product is a bispecific-antibody
    pipeline (MTX-101, MTX-201), not software — www.mozart-tx.com is an eight-page brochure site (about, science, pipeline,
    news, careers, contact) with no developer, docs or API section, no robots.txt or sitemap.xml, and a real HTTP 404 on every
    spec path probed (/openapi.json, /swagger.json, /graphql, /llms.txt, all five /.well-known/ documents); mozart-tx.com
    serves wildcard DNS so api./docs./developer./mcp. resolve to the marketing site's address but no TLS service answers on
    them, there is no GitHub organization under any Mozart spelling, and no first-party package exists on npm or PyPI.
  evidence:
  - url: https://www.mozart-tx.com/
    status: 200
  - url: https://www.mozart-tx.com/openapi.json
    status: 404
  - url: https://www.mozart-tx.com/llms.txt
    status: 404
  - url: https://www.mozart-tx.com/robots.txt
    status: 404
  - url: https://www.mozart-tx.com/.well-known/agent-card.json
    status: 404
  - url: https://www.mozart-tx.com/developers/
    status: 404
  - url: https://dev.mozart-tx.com/openapi.json
    status: 404
  - url: https://api.github.com/search/users?q=mozart-therapeutics
    status: 200
  - url: https://pypi.org/pypi/mozart-therapeutics/json
    status: 404
  checked: '2026-08-26'

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this
  • find_providersBrowse and filter every provider in the catalog.
  • get_provider_artifactsEvery artifact this provider publishes, grouped by type.
  • get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
  • get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
  • get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
  • get_provider_ratingPRO — composite, band, trend and facet scores.
  • apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
  • resolveTurn a domain, URL or GitHub org into the provider it belongs to.
  • find_cohortsEvery scored population of providers in the catalog.
All 92 tools →

Call it yourself

curl for this page
This provider
curl "https://apis.io/api/v1/providers/mozart-therapeutics"
All providers
curl "https://apis.io/api/v1/providers?limit=25"
Every operation they expose
curl "https://apis.io/api/v1/providers/mozart-therapeutics/operations?limit=25"
How their score was established
curl "https://apis.io/api/v1/providers/mozart-therapeutics/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

A second provider on the same verified email joins the account you already have.